CUMBERLAND PHARMACEUTICALS INC 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Purchases of Equity Securities We currently have a share repurchase program to purchase up to $10 million of our common stock pursuant to Rule 10b-18 of the Exchange Act. In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock. The following table summarizes the activity, by month, during the three months ended March 31, 2024: Period Total Number of Shares or Units Purchased, which were also Part of the Publicly Announced Plans or Programs Average Price Paid per Share (or Unit) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs Maximum number (or Approximate Dollar Value) of Shares (or Units) that May be Purchased Under the Publicly Announced Plan January 22,874 $2.08 $ 47,546 $ 2,957,839 February 22,630 $2.16 $ 48,775 $ 2,909,064 March 80,366 (1) $1.56 $ 150,278 $ 2,758,786 Total 125,870 (1) Of this amount, 51,607 shares were repurchased directly in private purchases at the then-current fair market value of common stock.